South Korea Diabetes Drugs Market Size Worth USD 4.9 Billion by 2033 | CAGR: 11.2%: IMARC Group

Market Overview 2025-2033

South Korea diabetes drugs market size reached USD 1.7 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.9 Billion by 2033, exhibiting a growth rate (CAGR) of 11.2% during 2025-2033. The market is expanding due to the rising prevalence of diabetes, aging demographics, and lifestyle changes. Growth is fueled by increased demand for oral antidiabetic drugs, advanced insulin therapies, and digital health tools. Technological innovations and government support are creating a dynamic and competitive landscape.

Key Market Highlights:

✔️ Strong market growth driven by rising diabetes prevalence and lifestyle-related health issues

✔️ Increasing adoption of advanced insulin therapies and oral antidiabetic drugs

✔️ Expanding government initiatives for early diagnosis, treatment access, and public health awareness

Request for a sample copy of the report: https://www.imarcgroup.com/south-korea-diabetes-drugs-market/requestsample

South Korea Diabetes Drugs Market Trends and Drivers:

The South Korea diabetes drugs market is experiencing strong and sustained momentum, driven by the rising prevalence of type 2 diabetes, which is closely linked to sedentary lifestyles, an aging population, and changing dietary habits. According to the Korean Diabetes Association, over 14% of adults aged 30 and above are currently living with diabetes, a number that continues to climb. This growing public health challenge has accelerated the adoption of advanced pharmacological therapies such as GLP-1 receptor agonists (e.g., semaglutide) and SGLT2 inhibitors (e.g., dapagliflozin), which provide additional benefits including cardiovascular and kidney protection.

In response to this increasing burden, domestic pharmaceutical leaders like Hanmi Pharmaceutical and Daewoong Pharmaceutical have ramped up research and development in 2024 to produce next-generation treatments. These efforts aim to reduce dependency on imports and reinforce local production capacity. Government policy has also played a pivotal role—expanded reimbursement schemes for innovative diabetes treatments have significantly improved patient access, fueling further South Korea diabetes drugs market growth.

Strategic partnerships are reshaping the competitive landscape. Multinational firms are teaming up with South Korean companies to streamline distribution and tap into the country’s advanced biosimilar development ecosystem. A standout example in 2024 was the collaboration between Novo Nordisk and Samsung Bioepis to co-develop biosimilar insulin, designed to lower costs and improve accessibility. Local manufacturers like Celltrion and Chong Kun Dang are also advancing biosimilars for drugs such as insulin glargine and liraglutide, heightening competition and prompting global brands to revisit their pricing strategies.

These developments are shifting South Korea diabetes drugs market share, as domestic firms increase their presence both locally and internationally. This progress is supported by national initiatives like the “K-Bio Health 2030” strategy, which aims to position South Korea as a global hub for biosimilars and biopharmaceutical innovation.

Technology continues to influence diabetes care delivery. Although AI-powered tools have become prominent, the broader trend is the integration of digital healthcare solutions—such as telemedicine platforms, connected glucose monitors, and electronic health record integration—that enhance chronic disease management. Startups like MediBloc and Noom are working closely with healthcare providers to deliver real-time monitoring and personalized treatment planning.

In 2024, the Ministry of Food and Drug Safety (MFDS) approved several next-generation diabetes management devices, reflecting strong regulatory support for innovation. Concurrently, advancements in pharmacogenomics—led by research institutions like Seoul National University Hospital—are paving the way for personalized treatment approaches, optimizing drug selection based on genetic profiles. These innovations contribute to improved patient outcomes and reinforce the long-term South Korea diabetes drugs market growth trajectory.

The market is also undergoing a shift toward fixed-dose combination therapies, particularly those that pair metformin with SGLT2 inhibitors. These combinations are gaining popularity for their convenience and adherence benefits. Preventive strategies have gained ground as well, with the National Health Insurance Service (NHIS) launching nationwide campaigns in 2024 to promote early detection and lifestyle interventions, aligning with broader goals of value-based care.

In 2024, the South Korea diabetes drugs market size surpassed $1.2 billion, underpinned by increasing adoption of biologics, biosimilars, and digital therapeutics. However, cost management remains a pressing issue. Policymakers have introduced reference pricing and generic substitution incentives to control healthcare spending. Digital therapeutics—such as mobile applications that assist with diet tracking and insulin dosing—are becoming an integral part of hybrid care models.

Global pharmaceutical companies like Lilly and AstraZeneca continue to invest in South Korea’s world-class clinical trial infrastructure to test advanced therapies, including dual GLP-1/GIP receptor agonists that promise improvements in both blood sugar control and weight management.

Looking ahead, cross-sector collaboration—particularly between pharmaceutical and tech companies—is expected to drive the next wave of innovation, including IoT-enabled drug delivery systems. To maintain progress, however, stakeholders must navigate evolving regulations and strike a balance between innovation and affordability. With strong R&D capabilities, forward-thinking policies, and a commitment to healthcare modernization, the South Korea diabetes drugs market is well-positioned for continued growth and increased competitiveness on the global stage.

South Korea Diabetes Drugs Market Segmentation: 

The report segments the market based on product type, distribution channel, and region:

Study Period:

Base Year: 2024

Historical Year: 2019-2024

Forecast Year: 2025-2033

Breakup by Drugs:

• Insulins

• Basal or Long Acting Insulins

• Bolus or Fast Acting Insulins

• Traditional Human Insulins

• Biosimilar Insulins

• Oral Anti-diabetic Drugs

• Biguanides

• Alpha-Glucosidase Inhibitors

• Dopamine D2 Receptor Agonist

• SGLT-2 Inhibitors

• DPP-4 Inhibitors

• Sulfonylureas

• Meglitinides

• Non-Insulin Injectable Drugs

• GLP-1 Receptor Agonists

• Amylin Analogue

• Combination Drugs

• Insulin Combinations

• Oral Combinations

Breakup by Distribution Channel:

• Online Pharmacies

• Hospital Pharmacies

• Retail Pharmacies

Breakup by Region:

• Seoul Capital Area

• Yeongnam (Southeastern Region)

• Honam (Southwestern Region)

• Hoseo (Central Region)

• Others

Competitive Landscape:

The market research report offers an in-depth analysis of the competitive landscape, covering market structure, key player positioning, top winning strategies, a competitive dashboard, and a company evaluation quadrant. Additionally, detailed profiles of all major companies are included.

Contact Us: 

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145